An update on the management of relapsed and primary refractory Hodgkin's disease Journal Article
| Author: | Moskowitz, C. |
| Article Title: | An update on the management of relapsed and primary refractory Hodgkin's disease |
| Abstract: | With the use of combined modality therapy for early stage disease and a risk-adapted approach for advanced stage disease, nearly 90% of patients with Hodgkin's lymphoma are cured with initial therapy. However, in patients who have primary refractory or relapsed disease, high-dose therapy and autologous stem cell transplantation is the best curative option. The use of peripheral blood progenitor cells has decreased transplant related mortality to less than 3%; but long-term progression-free survival as increased minimally. Although prognostic factors have been used to tailor therapy in de novo Hodgkin's lymphoma their utility in the relapsed-refractory setting has not been exploited. This update will discuss these important prognostic factors and try to guide oncologists in treatment decisions in this setting. © 2004 Elsevier Inc. All rights reserved. |
| Keywords: | cancer survival; survival analysis; prednisone; cancer recurrence; cisplatin; doxorubicin; multimodality cancer therapy; conference paper; cytarabine; cancer staging; drug megadose; antineoplastic agent; neoplasm recurrence, local; etoposide; antineoplastic combined chemotherapy protocols; risk factors; vincristine; stem cell transplantation; cancer mortality; chlormethine; ifosfamide; procarbazine; vinblastine; hodgkin disease; stem cell; bleomycin; methylprednisolone; hematopoietic stem cell mobilization; transplantation, autologous; autologous hematopoietic stem cell transplantation; humans; prognosis; human; priority journal |
| Journal Title: | Seminars in Oncology |
| Volume: | 31 |
| Issue: | 2 Suppl. 4 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2004-04-01 |
| Start Page: | 54 |
| End Page: | 59 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 15124135 |
| DOI: | 10.1053/j.seminoncol.2004.02.016 |
| DOI/URL: | |
| Notes: | Semin. Oncol. -- Cited By (since 1996):13 -- Export Date: 16 June 2014 -- CODEN: SOLGA -- Source: Scopus |
